These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21410863)

  • 1. Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.
    Agarwal N; Vogelzang NJ
    BJU Int; 2011 Jul; 108(2):227-8. PubMed ID: 21410863
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
    BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
    Klotz L; Schellhammer P; Carroll K
    BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600
    [No Abstract]   [Full Text] [Related]  

  • 5. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
    Duchesne GM; Syme R; Howell D
    J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary hormonal manipulations in the management of advanced prostate cancer.
    Chaudhary UB; Rashid MH; Onitilo AA; Bissada NK
    Can J Urol; 2005 Jun; 12(3):2666-76. PubMed ID: 16011813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
    Bryce A; Ryan CJ
    Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
    Nakabayashi M; Oh WK; Jacobus S; Regan MM; Taplin ME; Kantoff PW; Rosenberg JE
    BJU Int; 2010 May; 105(10):1392-6. PubMed ID: 19863532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary hormonal therapy.
    Smith DC
    Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
    Drewa T
    Eur Urol; 2010 Jul; 58(1):e4; author reply e5-6. PubMed ID: 20363067
    [No Abstract]   [Full Text] [Related]  

  • 12. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
    Moul JW; Zlotta AR
    BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
    [No Abstract]   [Full Text] [Related]  

  • 13. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer.
    Keisner SV; Shah SR; Jean GW; Ussery SM; Dowell JE
    Ann Pharmacother; 2010 Oct; 44(10):1538-44. PubMed ID: 20841515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Castration of prostate cancer patients and cognition].
    Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
    Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
    Bostwick DG
    Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone measurement in patients with prostate cancer.
    Schulman CC; Irani J; Morote J; Schalken JA; Montorsi F; Chlosta PL; Heidenreich A
    Eur Urol; 2010 Jul; 58(1):65-74. PubMed ID: 20434831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.